Table 2.
Summary of potential saliva biomarkers for gastric cancer screening and early diagnosis.
| Sample | Type | Biomarker | Patients | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Ref. |
|---|---|---|---|---|---|---|---|
| Saliva Biomarkers | |||||||
| Saliva | miRNA + mRNA | 3 mRNAs (SPINK7, PPL, and SEMA4B) and 2 miRNAs (MIR140-5p and MIR301a) + demographic | 294 patients (131 healthy patients and 163 GC patients) | 0.87 (0.80–0.93) | 82.00 | 77.00 | [69] |
| Saliva + blood | Protein + mRNA | CEA + mRNA PPL | 400 patients (200 healthy patients and 200 GC patients) | - | 92.00 | 87.00 | [70] |
| Saliva | Protein | CSTB + TPI1 + DMBT1 | 80 patients (40 healthy patients and 40 GC patients) | 0.93 | 85.00 | 80.00 | [71] |
| Saliva | Protein glycosylation | Salivary glycopattern (for GC VVA and SBA) (for atrophic gastritis DSA and LEL) | 201 patients (60 healthy patients, 87 GC patients, and 54 atrophic gastritis patients) | GC: 0.89 Atrophic gastritis: 0.83 |
GC: 0.96 Atrophic gastritis: 0.92 |
GC:0.80 Atrophic gastritis: 0.72 |
[72] |
GC, gastric cancer; AUC, area under the curve; Ref, reference; -, no data available.